-
Roussel Uclaf S.A. was a
French pharmaceutical company and one of
several predecessor companies of today's Sanofi. It was the
second largest French pharmaceutical...
-
mifepristone for
personal use in 1989, a
decision supported by
Roussel Uclaf. In 1994,
Roussel Uclaf gave the U.S. drug
rights to the Po****tion
Council in exchange...
- He
later obtained an MBA at HEC Paris. In
April 1986, he
joined Roussel Uclaf (formerly France's
second largest pharmaceutical company,
until bought by...
-
Julien Gaston Roussel, who was
President and
General Manager of the
Roussel Uclaf Laboratoires Pharmaceutiques, and his wife,
Francine Grinda,
daughter of...
- the
French pharmaceutical company Roussel-
Uclaf. In 1997,
after buying the
remaining 43.5% of Roussel-
Uclaf stock in
early 1997,
Hoechst AG announced...
-
antiandrogen (NSAA)
which was
initially developed in the 1980s by
Roussel Uclaf, the
French pharmaceutical company from
which it
received its name. It was...
- Roxithromycin's half-life is 12 hours.
French pharmaceutical company Roussel Uclaf first marketed roxithromycin in 1987.
Fischer J,
Ganellin CR (2006). Analogue-based...
- of St Ivel;
Patheon UK (pharmaceuticals, on the
former site of
Roussel Uclaf) are on the B4006 in Covingham,
north of Valero, in the east of Swindon...
- The drug
appears to have been an
early development project of
Roussel Uclaf, a
French pharmaceutical company, and by the
early 1970s, it was
being sold...
- anti-mineralocorticoids. The main
active companies were Searle, Ciba-Geigy,
Roussel Uclaf and
Schering AG.
Around 50
years after Selye's work,
several pharmaceutical...
